1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

 \parallel

 \parallel

 \parallel

//

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
OAKLAND DIVISION

CHRISTOPHER CORCORAN, et al.,

Plaintiffs,

CVS PHARMACY, INC.,

v.

Defendant.

No. 15-CV-03504-YGR

[PROPOSED] ORDER GRANTING DEFENDANT'S ADMINISTRATIVE MOTION TO FILE UNDER SEAL RE: SUMMARY JUDGMENT BRIEFING

Dkt. Nos. 281, 321

AS MODIFIED BY THE COURT

CVS Pharmacy, Inc. ("CVS") filed an Administrative Motion to File Under Seal re: Summary Judgment Briefing ("Motion to Seal") in the above-captioned action on June 6, 2017 pursuant to Local Rules 7-11 and 79-5. CVS also inadvertently filed another Exhibit, DX 456 (Dkt. No. 301-32), in the public docket, which contained Plaintiffs' private medical information. CVS has now requested the Court lock that Exhibit and re-filed it under seal. Dkt. No. 321. Plaintiffs filed a declaration in support of filing their private health information under seal, but otherwise took no position as to CVS's other requests. *See* Sweeney Decl. (filed July 12, 2017). For good cause appearing, the Court **GRANTS** CVS's request. The Clerk shall **PERMANENTLY LOCK** Docket Number 301-32.

The Court, having considered CVS's Motion to Seal, all papers and evidence submitted in support, the pertinent pleadings, and the applicable law, and finding compelling reasons and good cause therefore, hereby **GRANTS IN PART** the Motion to Seal. It is **ORDERED** that the following materials are to be filed under seal pursuant to Civil Local Rule 79-5(b) and (e):

- 1 -

[PROPOSED] ORDER GRANTING ADMINISTRATIVE MOTION TO FILE UNDER SEAL, NO. 15-CV-03504-YGR

Document or Portion of Document	Evidence Offered in	Order
Sought to Be Sealed	Support of Sealing	
OX-006 (Plaintiff Carolyn Caine's	Moffatt Declaration ¶¶ 5, 5.a;	GRANT
Amended Responses and Objections	Sweeney Decl. ¶¶ 5-6	
o Defendant's Interrogatories (July		
22, 2016)) at page 3 line 20; page 7		
ine 22; and page 8 lines 12-13.		
OX-028 (Plaintiff Robert Jenks'	Moffatt Declaration ¶¶ 5,	GRANT
Amended Responses and Objections	5.b; Sweeney Decl. ¶¶ 5-6	
o Defendant's Interrogatories (July		
22, 2016)) at page 3 lines 20-23;		
page 8 lines 2-3, 16-17, 21-22, and		
26; and page 9 lines 8-9		
DX-083 (Plaintiff Walter Wulff's	Moffatt Declaration ¶¶ 5, 5.c;	GRANT
Amended Responses and Objections	Sweeney Decl. ¶¶ 5-6	
o Defendant's Interrogatories (Aug.		
I, 2016)) at page 3 lines 18-19; page		
7 lines 17-18; and page 8 lines 10,		
15, and 18-19.		
DX-092 (Plaintiff Zachary Hagert's	Moffatt Declaration ¶¶ 5,	GRANT
Amended Responses and Objections	5.d; Sweeney Decl. ¶¶ 5-6	
o Defendant's Interrogatories (Aug.		
5, 2016)) at page 3 lines 20-25; page		
B lines 2 and 14-15.		
DX-102 (Plaintiff Toni Odorisio's	Moffatt Declaration ¶¶ 5, 5.e;	GRANT

1	Amended Reponses and Objections	Sweeney Decl. ¶¶ 5-6	
2	to Defendant's Interrogatories (Aug.		
3	1, 2016)) at page 3 line 21; page 7		
4	lines 17-19; page 8 lines 9, 14-15,		
5	and 19-20; and page 9 lines 1-2, 6-7,		
6	and 12.		
7	DX-118 (Plaintiff Onnolee	Moffatt Declaration ¶¶ 5, 5.f;	GRANT
8	Samuelson's Third Amended	Sweeney Decl. ¶¶ 5-6	
9	Responses and Objections to		
0	Defendant's Interrogatories (Aug.		
1	17, 2016)) at page 3 lines 18-19;		
2	page 7 lines 20-21; page 8 lines 10,		
3	14-15, 18-19, and 23; page 9 lines 1,		
4 5	5-6, 10, 15, 20, and 25; page 10 lines		
5	2-3, 7, 12, 17, 22-23; and page 11		
6	lines 1-2 and 7.		
7	DX-165 (Plaintiff Vincent	Moffatt Declaration ¶¶ 5,	GRANT
8	Gargiulo's Second Amended	5.g; Sweeney Decl. ¶¶ 5-6	
9	Responses and Objections to		
0	Defendant's Interrogatories Aug. 27,		
1	2016)) at page 3 lines 20-21; and		
2	page 8 lines 6-7, 21, and 25-26.		
3	DX-185 (Plaintiff Carl Washington's	Moffatt Declaration ¶¶ 5,	GRANT
4	Amended Responses and Objections	5.h; Sweeney Decl. ¶¶ 5-6	
5	to Defendant's Interrogatories (Aug.		
6	23, 2016)) at page 3 lines 18-21;		
7	page 7 line 27; and page 8 lines 15,		
28			ROPOSEDI ORDER GRANTING

20, and 24-25.		CDANE
DX-193 (Plaintiff Amanda Gilbert's	Moffatt Declaration ¶¶ 5, 5.i;	GRANT
Amended Responses and Objections	Sweeney Decl. ¶¶ 5-6	
to Defendant's Interrogatories (Aug.		
25, 2016)) at page 3 lines 19-22;		
page 8 at lines 10-13, 23; page 9		
lines 4, 11-12, 17, and 21-22; and		
page 10 lines 1-2, 5-6, and 10-11.		~
DX-201 (Plaintiff Zulema Avis's	Moffatt Declaration ¶¶ 5, 5.j;	GRANT
Amended Responses and Objections	Sweeney Decl. ¶¶ 5-6	
to Defendant's Interrogatories (Aug.		
1, 2016)) at page 3 line 18; page 7		
lines 17-18; page 8 lines 6-7, 10-11;		
and page 9 line 7.		
DX-217 (Plaintiff Debbie Barrett's	Moffatt Declaration ¶¶ 5,	GRANT
Second Amended Responses and	5.k; ; Sweeney Decl. ¶¶ 5-6	
Objections to Defendant's		
Interrogatories (Sept. 13, 2016)) at		
page 3 lines 18-20; page 7 lines 25-		
26; page 8 lines 13-14, 17-18, 21-22,		
25-26; page 9 lines 2-3, 6-7, 10-11,		
18-19, 22-23, 26; page 10 lines 1, 4-		
5, 8-9, 12-13, 16-17, 20-21, 24-25;		
page 11 lines 2-3, 6-7, 10-11, 18-19,		
22-23, 26; and page 12 lines 1, 4-5,		
8-9.		~
DX-218 (Plaintiff Robert Garber's	Moffatt Declaration ¶¶ 5, 5.l;	GRANT

SEAL, NO. 15-CV-03504-YGR

	1	1
Amended Responses and Objections	Sweeney Decl. ¶¶ 5-6	
to Defendant's Interrogatories (Aug.		
1, 2016)) at page 3 line 18; page 7		
lines 15-18; page 8 lines 6-7, 10-11,		
14-15, 19-20, 24-25; page 9 lines 1-		
2, 6-7, 11, 15-16, 19-20, 24; page 10		
lines 2-3, 8, 17, 21-22; and page 11		
lines 1-2, 7, and 12.		
DX-239 (Plaintiff Gilbert Brown's	Moffatt Declaration ¶¶ 5,	GRANT
Amended Responses and	5.m; Sweeney Decl. ¶¶ 5-6	
Objection's to Defendant's		
Interrogatories (Oct. 5, 2016)) at		
page 3 line 19; page 7 line 18; and		
page 8 lines 1-2, 5-6, 10-11.		
DX-258 (Plaintiff Tyler Clark's	Moffatt Declaration ¶¶ 5,	GRANT
Supplemental and Amended	5.n; Sweeney Decl. ¶¶ 5-6	
Responses and Objections to		
Defendant's Interrogatories (Oct. 7,		
2016)) at page 3 line 18; page 7 line		
24; and page 8 lines 11-12, 15-16.		
DX-266 (Medco Pharmacy Services	Moffatt Declaration ¶¶ 4, 4.a	GRANT IN PART, except as to sections
Manual (2009/2010))		relating to: 1) Usual &
		Customary definitions and provisions; and 2)
		Third-Party beneficiaries
DX-270 (Plaintiff Christopher	Moffatt Declaration 5, 5.0;	GRANT
Corcoran's Supplemental and	Sweeney Decl. ¶¶ 5-6	
Amended Responses and Objections		
The second second second second		 ROPOSED ORDER GRANTIN

and provisions; and 2) Third-Party beneficiariesDX-408 (Expert Report of Brett E. Barlag (Dec. 9, 2016)) at page 8 ¶Moffatt Declaration ¶¶ 6, 6.aGRANT IN PART, except as to paragraph 72.22; page 11 ¶ 27.c, Fig. 1, fn. 8; page 12 ¶ 29; page 13 ¶¶ 33-37; page 15Moffatt Declaration ¶¶ 6, 6.aGRANT IN PART, except as to paragraph 72.9; page 19 ¶ 51; page 24 Fig. 12, ¶ 65; page 25 ¶¶ 66-68; page 26 ¶¶ 68- 71, Fig. 13, fn. 60; page 27 ¶ 72; page 29 Fig. 16; page 38 ¶¶ 102-103; page 39 ¶ 105, fns. 92-93; page 40 ¶ 106; page 42 ¶¶ (b), 116; page 43 ¶¶ 116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix Eand provisions; and 2) Third-Party beneficiaries			
7 lines 22-24; page 8 lines 14, 18-19, 24; page 9 lines 2-3, 8, 13, 18-19, 23; page 10 lines 3-4, 8, 12-13, 16- 17, 21; and page 11 lines 1-2, 6-7, 13-14, and 18. DX-300 (MedImpact Pharmacy Network Agreement (Feb. 1, 2008)) Network Agreement (Feb. 1, 2008)) DX-408 (Expert Report of Brett E. Barlag (Dec. 9, 2016)) at page 8 ¶ 22; page 11 ¶ 27.c, Fig. 1, fn. 8; page 12 ¶ 29; page 13 ¶¶ 33-37; page 15 Fig. 4; page 17 Fig. 7; page 18 Fig. 9; page 25 ¶¶ 66-68; page 26 ¶¶ 68- 71, Fig. 13, fn. 60; page 27 ¶ 72; page 39 ¶ 105, fns. 92-93; page 40 ¶ 106; page 42 ¶[(b), 116; page 43 ¶¶ 116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix E	to Defendant's Interrogatories (Oct.		
24; page 9 lines 2-3, 8, 13, 18-19, 23; page 10 lines 3-4, 8, 12-13, 16- 17, 21; and page 11 lines 1-2, 6-7, 13-14, and 18. DX-300 (MedImpact Pharmacy Network Agreement (Feb. 1, 2008)) Moffatt Declaration ¶¶ 4, 4b Customary definitions and provisions; and 2) Third-Party beneficiaries DX-408 (Expert Report of Brett E. Barlag (Dec. 9, 2016)) at page 8 ¶ 22; page 11 ¶ 27.c, Fig. 1, fn. 8; page 12 ¶ 29; page 13 ¶¶ 33-37; page 15 Fig. 4; page 17 Fig. 7; page 18 Fig. 9; page 29 ¶ 51; page 24 Fig. 12, ¶ 65; page 25 ¶¶ 66-68; page 26 ¶¶ 68- 71, Fig. 13, fn. 60; page 27 ¶ 72; page 39 ¶ 105, fns. 92-93; page 40 ¶ 106; page 42 ¶¶ (b), 116; page 43 ¶¶ 116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix E	7, 2016)) at page 3 lines 18-19; page		
23; page 10 lines 3-4, 8, 12-13, 16- 17, 21; and page 11 lines 1-2, 6-7, 13-14, and 18. DX-300 (MedImpact Pharmacy Network Agreement (Feb. 1, 2008)) Network Agreement (Feb. 1, 2008)) Moffatt Declaration ¶¶ 4, 4b GRANT IN PART, except as to sections and provisions; and 2) Third-Party beneficiaries DX-408 (Expert Report of Brett E. Barlag (Dec. 9, 2016)) at page 8 ¶ 22; page 11 ¶ 27.c, Fig. 1, fn. 8; page 12 ¶ 29; page 13 ¶¶ 33-37; page 15 Fig. 4; page 17 Fig. 7; page 18 Fig. 9; page 19 ¶ 51; page 24 Fig. 12, ¶ 65; page 25 ¶¶ 66-68; page 26 ¶¶ 68- 71, Fig. 13, fn. 60; page 27 ¶ 72; page 29 Fig. 16; page 38 ¶¶ 102-103; page 39 ¶ 105, fns. 92-93; page 40 ¶ 106; page 42 ¶¶ (b), 116; page 43 ¶¶ 116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix E	7 lines 22-24; page 8 lines 14, 18-19,		
17, 21; and page 11 lines 1-2, 6-7, 13-14, and 18. DX-300 (MedImpact Pharmacy Network Agreement (Feb. 1, 2008)) Moffatt Declaration ¶¶ 4, 4b GRANT IN PART, except as to sections relating to: 1) Usual Customary definitions and provisions; and 2) Third-Party beneficiaries DX-408 (Expert Report of Brett E. Barlag (Dec. 9, 2016)) at page 8 ¶ 22; page 11 ¶ 27.c, Fig. 1, fn. 8; page 12 ¶ 29; page 13 ¶¶ 33-37; page 15 Fig. 4; page 17 Fig. 7; page 18 Fig. 9; page 19 ¶ 51; page 24 Fig. 12, ¶ 65; page 25 ¶¶ 66-68; page 26 ¶¶ 68- 71, Fig. 13, fn. 60; page 27 ¶ 72; page 39 ¶ 105, fns. 92-93; page 40 ¶ 106; page 42 ¶¶ (b), 116; page 43 ¶¶ 116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix E	24; page 9 lines 2-3, 8, 13, 18-19,		
13-14, and 18.Moffatt Declaration ¶¶ 4, 4bGRANT IN PART, except as to sections relating to: 1) Usual A Customary definitions and provisions; and 2) Third-Party beneficiariesDX-408 (Expert Report of Brett E. Barlag (Dec. 9, 2016)) at page 8 ¶ 22; page 11 ¶ 27.c, Fig. 1, fn. 8; page 12 ¶ 29; page 13 ¶¶ 33-37; page 15 Fig. 4; page 17 Fig. 7; page 18 Fig. 9; page 19 ¶ 51; page 24 Fig. 12, ¶ 65; page 25 ¶¶ 66-68; page 26 ¶¶ 68- 71, Fig. 13, fn. 60; page 27 ¶ 72; page 29 Fig. 16; page 38 ¶¶ 102-103; page 39 ¶ 105, fns. 92-93; page 40 ¶ 106; page 42 ¶¶ (b), 116; page 43 ¶¶ 116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix EMoffatt Declaration ¶¶ 4, 4bGRANT IN PART, except as to sections relating to: 1) Usual A Customary definitions and provisions; and 2) Third-Party beneficiaries	23; page 10 lines 3-4, 8, 12-13, 16-		
DX-300 (MedImpact Pharmacy Network Agreement (Feb. 1, 2008))Moffatt Declaration ¶¶ 4, 4bGRANT IN PART, except as to sections relating to: 1) Usual & Customary definitions and provisions; and 2) Third-Party beneficiariesDX-408 (Expert Report of Brett E. Barlag (Dec. 9, 2016)) at page 8 ¶ 22; page 11 ¶ 27.c, Fig. 1, fn. 8; page 12 ¶ 29; page 13 ¶ 33-37; page 15 Fig. 4; page 17 Fig. 7; page 18 Fig. 9; page 19 ¶ 51; page 24 Fig. 12, ¶ 65; page 25 ¶ 66-68; page 26 ¶ 68- 71, Fig. 13, fn. 60; page 27 ¶ 72; page 39 ¶ 105, fns. 92-93; page 40 ¶ 106; page 42 ¶¶ (b), 116; page 43 ¶¶ 116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix EMoffatt Declaration ¶¶ 4, 4bGRANT IN PART, except as to sections relating to: 1) Usual & Customary definitions and provisions; and 2) Third-Party beneficiaries	17, 21; and page 11 lines 1-2, 6-7,		
DX-300 (MedImpact Pharmacy Network Agreement (Feb. 1, 2008))Moffatt Declaration ¶¶ 4, 4bexcept as to sections relating to: 1) Usual & Customary definitions and provisions; and 2) Third-Party beneficiariesDX-408 (Expert Report of Brett E. Barlag (Dec. 9, 2016)) at page 8 ¶ 22; page 11 ¶ 27.c, Fig. 1, fn. 8; page 12 ¶ 29; page 13 ¶¶ 33-37; page 15 Fig. 4; page 17 Fig. 7; page 18 Fig. 9; page 19 ¶ 51; page 24 Fig. 12, ¶ 65; page 25 ¶¶ 66-68; page 26 ¶¶ 68- 71, Fig. 13, fn. 60; page 27 ¶ 72; page 39 ¶ 105, fns. 92-93; page 40 ¶ 106; page 42 ¶¶ (b), 116; page 43 ¶¶ 116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix EMoffatt Declaration ¶¶ 4, 4b and provisions; and 2) Third-Party beneficiaries	13-14, and 18.		
$\begin{array}{c} \text{Customary definitions}\\ \text{and provisions; and 2)}\\ \text{Third-Party}\\ \text{beneficiaries}\\ \text{DX-408 (Expert Report of Brett E. \\ \text{Barlag (Dec. 9, 2016)) at page 8 ¶}\\ 22; page 11 ¶ 27.c, Fig. 1, fn. 8; page 12 ¶ 29; page 13 ¶¶ 33-37; page 15\\ Fig. 4; page 17 Fig. 7; page 18 Fig. 9; page 19 ¶ 51; page 24 Fig. 12, ¶\\ 65; page 25 ¶¶ 66-68; page 26 ¶¶ 68-71, Fig. 13, fn. 60; page 27 ¶ 72; page 39 ¶ 105, fns. 92-93; page 40 ¶\\ 106; page 42 ¶¶ (b), 116; page 43 ¶¶\\ 116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix E \\ \end{array}$	DX-300 (MedImpact Pharmacy	Moffatt Declaration ¶¶ 4, 4b	except as to sections
DX-408 (Expert Report of Brett E. Moffatt Declaration ¶¶ 6, 6.a GRANT IN PART, except as to paragraph 72. Barlag (Dec. 9, 2016)) at page 8 ¶ 22; page 11 ¶ 27.c, Fig. 1, fn. 8; page 72. 12 ¶ 29; page 13 ¶¶ 33-37; page 15 Fig. 4; page 17 Fig. 7; page 18 Fig. 72. 9; page 19 ¶ 51; page 24 Fig. 12, ¶ 65; page 25 ¶¶ 66-68; page 26 ¶¶ 68-71, Fig. 13, fn. 60; page 27 ¶ 72; 72. page 29 Fig. 16; page 38 ¶¶ 102-103; page 39 ¶ 105, fns. 92-93; page 40 ¶ 106; page 42 ¶¶ (b), 116; page 43 ¶¶ 116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix E	Network Agreement (Feb. 1, 2008))		Customary definitions
DX-408 (Expert Report of Brett E. Barlag (Dec. 9, 2016)) at page 8 ¶Moffatt Declaration ¶¶ 6, 6.a GRANT IN PART , except as to paragraph 72.22; page 11 ¶ 27.c, Fig. 1, fn. 8; page 12 ¶ 29; page 13 ¶¶ 33-37; page 15Fig. Fig. 4; page 17 Fig. 7; page 18 Fig. 9; page 19 ¶ 51; page 24 Fig. 12, ¶ 65; page 25 ¶¶ 66-68; page 26 ¶¶ 68- 71, Fig. 13, fn. 60; page 27 ¶ 72; page 29 Fig. 16; page 38 ¶¶ 102-103; page 39 ¶ 105, fns. 92-93; page 40 ¶ 106; page 42 ¶¶ (b), 116; page 43 ¶¶ 116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix EMoffatt Declaration ¶¶ 6, 6.a GRANT IN PART , except as to paragraph 72.			Third-Party
22; page 11 ¶ 27.c, Fig. 1, fn. 8; page 12 ¶ 29; page 13 ¶¶ 33-37; page 15 Fig. 4; page 17 Fig. 7; page 18 Fig. 9; page 19 ¶ 51; page 24 Fig. 12, ¶ 65; page 25 ¶¶ 66-68; page 26 ¶¶ 68- 71, Fig. 13, fn. 60; page 27 ¶ 72; page 29 Fig. 16; page 38 ¶¶ 102-103; page 39 ¶ 105, fns. 92-93; page 40 ¶ 106; page 42 ¶¶ (b), 116; page 43 ¶¶ 116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix E	DX-408 (Expert Report of Brett E.	Moffatt Declaration ¶¶ 6, 6.a	
12 ¶ 29; page 13 ¶¶ 33-37; page 15 Fig. 4; page 17 Fig. 7; page 18 Fig. 9; page 19 ¶ 51; page 24 Fig. 12, ¶ 65; page 25 ¶¶ 66-68; page 26 ¶¶ 68- 71, Fig. 13, fn. 60; page 27 ¶ 72; page 29 Fig. 16; page 38 ¶¶ 102-103; page 39 ¶ 105, fns. 92-93; page 40 ¶ 106; page 42 ¶¶ (b), 116; page 43 ¶¶ 116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix E	Barlag (Dec. 9, 2016)) at page 8 ¶		72.
Fig. 4; page 17 Fig. 7; page 18 Fig. 9; page 19 ¶ 51; page 24 Fig. 12, ¶ 65; page 25 ¶¶ 66-68; page 26 ¶¶ 68- 71, Fig. 13, fn. 60; page 27 ¶ 72; page 29 Fig. 16; page 38 ¶¶ 102-103; page 39 ¶ 105, fns. 92-93; page 40 ¶ 106; page 42 ¶¶ (b), 116; page 43 ¶¶ 116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix E	22; page 11 ¶ 27.c, Fig. 1, fn. 8; page		
9; page 19 ¶ 51; page 24 Fig. 12, ¶ 65; page 25 ¶¶ 66-68; page 26 ¶¶ 68- 71, Fig. 13, fn. 60; page 27 ¶ 72; page 29 Fig. 16; page 38 ¶¶ 102-103; page 39 ¶ 105, fns. 92-93; page 40 ¶ 106; page 42 ¶¶ (b), 116; page 43 ¶¶ 116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix E	12 ¶ 29; page 13 ¶¶ 33-37; page 15		
65; page 25 ¶¶ 66-68; page 26 ¶¶ 68- 71, Fig. 13, fn. 60; page 27 ¶ 72; page 29 Fig. 16; page 38 ¶¶ 102-103; page 39 ¶ 105, fns. 92-93; page 40 ¶ 106; page 42 ¶¶ (b), 116; page 43 ¶¶ 116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix E	Fig. 4; page 17 Fig. 7; page 18 Fig.		
71, Fig. 13, fn. 60; page 27 ¶ 72; page 29 Fig. 16; page 38 ¶¶ 102-103; page 39 ¶ 105, fns. 92-93; page 40 ¶ 106; page 42 ¶¶ (b), 116; page 43 ¶¶ 116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix E	9; page 19 ¶ 51; page 24 Fig. 12, ¶		
page 29 Fig. 16; page 38 ¶¶ 102-103; page 39 ¶ 105, fns. 92-93; page 40 ¶ 106; page 42 ¶¶ (b), 116; page 43 ¶¶ 116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix E	65; page 25 ¶¶ 66-68; page 26 ¶¶ 68-		
page 39 ¶ 105, fns. 92-93; page 40 ¶ 106; page 42 ¶¶ (b), 116; page 43 ¶¶ 116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix E	71, Fig. 13, fn. 60; page 27 ¶ 72;		
106; page 42 ¶¶ (b), 116; page 43 ¶¶ 116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix E	page 29 Fig. 16; page 38 ¶¶ 102-103;		
116-118, Fig. 20; page 44 Fig. 21; page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix E	page 39 ¶ 105, fns. 92-93; page 40 ¶		
page 47 ¶ 124, fn. 108; Appendix A; Appendix D; and Appendix E	106; page 42 ¶¶ (b), 116; page 43 ¶¶		
Appendix D; and Appendix E	116-118, Fig. 20; page 44 Fig. 21;		
	page 47 ¶ 124, fn. 108; Appendix A;		
	Appendix D; and Appendix E		
DX-409 (Rebuttal Report of Brett E. Moffatt Declaration ¶¶ 6, 6.b except as to paragraph		Moffatt Declaration ¶¶ 6, 6.b	GRANT IN PART , except as to paragraphs
Barlag (Jan. 27, 2017)) at page 3 fn. 23 and 23.b [PROPOSED] ORDER GRANTI	Barlag (Jan. 27, 2017)) at page 3 fn.	<u></u>	

r			1
	3; page 11 ¶¶ 23, 23.b; page 12 ¶¶		
	23.b, 26, fn. 28; page 13 ¶ 27; page		
	14 ¶¶ 28-29, Fig. 7; page 15 ¶¶ 29-		
	31, page 16 ¶ 32, Fig. 8; page 17 ¶¶		
	36.a, 36.b, fn. 39; page 19 ¶ 38; and		
	Appendix B;		
	DX-425 (Declaration of Susan	Moffatt Omnibus	GRANT IN PART , except as to paragraph
	Colbert (Nov. 21, 2016)) at page 1	Declaration ¶ 27(b)	13. The specific
	¶¶ 3-4; page 2 ¶¶ 7-9; page 3 ¶¶ 9-		Condor Codes referenced therein may
	12; page 4 ¶¶13-14; page 5 ¶¶ 14-16;		remain sealed.
	and page 6 ¶18.		
	DX-446 (Express Scripts Provider	Moffatt Declaration ¶¶ 4, 4.c	GRANT IN PART, except as to sections
	Manual (2014))		relating to: 1) Usual & Customary definitions
			and provisions; and 2)
			Third-Party beneficiaries
	DX-447 (Seventh Amendment to	Moffatt Declaration ¶¶ 4, 4.d	GRANT IN PART, except as to sections
	Express Scripts, Inc. Pharmacy		relating to: 1) Usual &
	Provider Agreement (Feb. 11, 2013)		Customary definitions and provisions; and 2)
			Third-Party beneficiaries
	DX-459 (Deposition Excerpts of	Moffatt Declaration ¶¶ 5,	GRANT
	Plaintiff Zulema Avis (Aug. 5,	5.p; Sweeney Decl. ¶¶ 5-6	
	2016)) at page 142 lines 7-14; and		
	page 144 lines 8-14.		
	DX-464 (Deposition Excerpts of	Moffatt Declaration ¶¶ 5,	GRANT
	Plaintiff Christopher Corcoran (Nov.	5.q; Sweeney Decl. ¶¶ 5-6	
	L N	▲····· ♥ Ⅱ Ⅲ	
	2, 2016)) at page 84 lines 9-10; and		

DX-466 (Deposition Excerpts of	Moffatt Declaration ¶¶ 5, 5.r;	GRANT
Plaintiff Vincent Garguilo (Aug. 27,	Sweeney Decl. ¶¶ 5-6	
2016)) at page 128 lines 22-23; page		
130 lines 17-19, 21-24; page 132		
lines 8-11; page 174 lines 19-22; and		
page 176 lines 15-21.		
DX-467 (Deposition Excerpts of	Moffatt Declaration ¶¶ 5, 5.s;	GRANT
Plaintiff Amanda Gilbert (Sept. 7,	Sweeney Decl. ¶¶ 5-6	
2016)) at page 82 lines 18-20; page		
85 lines 18-24; page 148 lines 2-5;		
and page 149 lines 4-7.		
DX-469 (Deposition Excerpts of	Moffatt Declaration ¶¶ 5, 5.t;	GRANT
Plaintiff Robert Jenks (July 28,	Sweeney Decl. ¶¶ 5-6	
2016)) at page 138 lines 4, 16, 21;		
page 139 lines 2, 6, 16, 18, 19; page		
140 lines 4, 11, 17, 26; page 207 line		
18; page 208 lines 6, 17, 25; and		
page 209 line 13		
DX-472 (Deposition Excerpts of	Moffatt Declaration ¶¶ 5,	GRANT
Plaintiff Carl Washington (Aug. 30,	5.u; Sweeney Decl. ¶¶ 5-6	
2016)) at page 190 lines 3-4; page		
101 lines 8, 20; page 192 lines 5;		
page 269 lines 3; and page 306 lines		
2-3, 8.		
DX-473 (Deposition Excerpts of	Moffatt Declaration ¶¶ 5,	GRANT
Plaintiff Walter Wulff (Aug. 9,	5.v; Sweeney Decl. ¶¶ 5-6	
2016)) at page 72 line 21; and page		

73 at line 25		
PX-532 (Express Scripts, Inc.Pharmacy Provider Agreement (Jan.18, 2008))	Moffatt Declaration ¶¶ 4, 4.e	GRANT IN PART, except as to sections relating to: 1) Usual of Customary definitions and provisions; and 2 Third-Party beneficiaries
PX-546 (PCS Health Systems, Inc. Provider Agreement (Mar. 31, 1997))	Moffatt Declaration ¶¶ 4, 4.f	GRANT IN PART, except as to sections relating to: 1) Usual of Customary definitions and provisions; and 2 Third-Party beneficiaries
PX-551 (Medco Pharmacy Services Manual (2009))	Moffatt Declaration ¶¶ 4, 4.g	GRANT IN PART, except as to sections relating to: 1) Usual of Customary definitions and provisions; and 2 Third-Party beneficiaries
PX-615 (Express Scripts Network Provider Manual (2010))	Moffatt Declaration ¶¶ 4, 4.h	GRANT IN PART, except as to sections relating to: 1) Usual Customary definitions and provisions; and 2 Third-Party beneficiaries
PX-674 (OptumRx, Inc. Pharmacy Network Agreement (Jan. 29, 2015))	Moffatt Declaration ¶¶ 4, 4.i	GRANT IN PART, except as to sections relating to: 1) Usual of Customary definitions and provisions; and 2 Third-Party beneficiaries
PX-677 (Medco Health Solutions, Inc. Retail Pharmacy Agreement (Jan. 1, 2005)	Moffatt Declaration ¶¶ 4, 4.j	GRANT IN PART, except as to sections relating to: 1) Usual of Customary definitions and provisions; and 2 Third-Party beneficiaries
PX-679 (Caremark Provider Manual (2016))	Moffatt Declaration ¶¶ 4, 4.k	GRANT IN PART, except as to sections relating to: 1) Usual

1			Customary definitions
2			and provisions; and 2)
2			Third-Party
3			beneficiaries
	PX-695 (Prescription Solutions	Moffatt Declaration ¶¶ 4, 41	GRANT IN PART,
4	1 X 095 (1 rescription Solutions		except as to sections
5	Prescription Drug Services		relating to: 1) Usual &
5			Customary definitions
6	Agreement (June 1, 1999))		and provisions; and 2)
			Third-Party beneficiaries
7			
8	PX-703 (Network Performance,	Moffatt Declaration 7, 7.a	GRANT IN PART, except as to sections
0			relating to: 1) Usual &
9	Troubleshooting Set Price Generic		Customary definitions
10	Programs (Oct. 1, 2008))		and provisions; and 2)
10	110grams (000. 1, 2000))		Third-Party
11			beneficiaries
			GRANT IN PART,
12	PX-785 (Aetna Health Management	Moffatt Declaration 4, 4.m	except as to sections
12	National Pharmacy Services		relating to: 1) Usual &
13			Customary definitions
14	Agreement (Jan. 15, 2009)		and provisions; and 2)
			Third-Party
15			beneficiaries

17 Additional document to be sealed in response to CVS Motion to Remove Incorrectly Filed

18 Document (Dkt. No. 321):

16

26

27

28

19 20	Document or Portion of Document	Evidence Offered in Support of	Order
20	Sought to Be Sealed	Sealing	
21	DX-456 – Plaintiffs' prescription records	Sweeney Decl. ¶¶ 5-6	GRANT
22		• • • •	
23			

24 This Order terminates Docket Numbers 281 and 321.

25 **IT IS SO ORDERED.**

Dated: _September 5, 2017

nor Hon. Yvone Gonzalez Rogers United States District Court

- 10 - [PROPOSED] ORDER GRANTING ADMINISTRATIVE MOTION TO FILE UNDER SEAL, NO. 15-CV-03504-YGR